News & Updates

New drug applications approved by US FDA as of 16 - 30 November 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Among men seeking vasectomy reversal (VR) after testosterone therapy (TT), vasovasostomy (VV) appears to be a very common procedure that is likely to succeed.

Individuals with microscopic haematuria, especially persistent haematuria, appear to be at heightened risk of chronic kidney disease, as shown in a study.

External beam radiation therapy with low-dose rate brachytherapy boost appears to result in worse urinary irritative/obstructive and bowel functions but better urinary incontinence function through 5 years after treatment when compared to radical prostatectomy, reports a recent study.

Intrarectal povidone-iodine cleansing along with formalin disinfection of the biopsy needle tip helps reduce infectious complications following transrectal prostate biopsy, a study has shown.

In men with Peyronie’s disease (PD) treated with intralesional Collagenase Clostridium histolyticum (CCH), those with greater baseline curvature are more likely to achieve improvement, reaching up to 60 percent for patients with ≥60 degrees, a study has shown.

New drug applications approved by US FDA as of 01 - 15 November 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.